bluebird bio (BLUE) Breathtaking Beta-thalassemia Major Trial Data, BP plc (BP) Headwinds from Gulf Oil Spill |
Posted: December 9, 2014 |
Crown Equity Holdings Inc. (CRWE) CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites. One of the primary goals of the CRWE Network is to offer business owners the power of consumer targeting advertisements on a local and national scale. CRWE has recently included Victoria, the capital city of British Columbia, Canada ( www.victoriacanada.crwe-pr.com ) to the CRWE Network. On the southern tip of Vancouver Island, Victoria is a community of choice for its temperate climate, natural beauty, recreational sites and economic opportunities. Known as the "The Garden City", Victoria is an attractive city and a popular tourism destination with a thriving technology sector that has risen to be its largest revenue-generating private industry. With an estimated population in 2011 of approximately 80,017, Victoria, BC, Canada represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally The CRWE Network has reached the 1486th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada. The CRWE-PR Business Directory portal ( www.BusinessDirectory.crwe-pr.com ) is the company’s business directory service that is available to all United States and Canada business in the public and private sector. It allows business owners and executives the ability to claim their business listings and provide more detailed information for their potential customers who visit the CRWE Network everyday. CRWE plans to have full national coverage of all U.S and Canada businesses in the future on its CRWE-PR Business Directory, which will be integrated to the CRWE Network. The CRWE-PR Finance website ( www.finance.crwe-pr.com ) allows CRWE the instant distribution of information to the entire CRWE Network. Online video is gaining strength as a source for content marketing. Strategic plans are being developed for CRWE’s division CRWE Tube ( www.crwetube.com ) to improve the potential future growth for the company. More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com ** bluebird bio, Inc. (BLUE) The thalassemias are a group of genetic (inherited) blood disorders that share in common one feature, the defective production of hemoglobin, the protein that enables red blood cells to carry and deliver oxygen. Beta thalassemia is a blood disorder that reduces the production of hemoglobin. It is caused by abnormal or missing genes that affect the beta chain of the hemoglobin molecule. It is classified into two types depending on the severity of symptoms: thalassemia major (also known as Cooley's anemia) and thalassemia minor. Beta-thalassemia can cause severe anemia. Approximately 40,000 children are born with a serious form of the disease every year, making it one of the most common genetic diseases in the world. In its most severe form, beta-thalassemia is fatal if not treated. Treating beta-thalassemia includes frequent and lifelong blood transfusions, which deliver red blood cells to the body to correct the anemia. However, blood transfusions also cause excess iron to build up in the body, which can damage organs and cause additional issues, such as abdominal pain, weakness, fatigue, joint pain, endocrine dysfunction, liver cirrhosis and heart failure. Patients who receive ongoing blood transfusions must also receive treatment to remove the excess iron. The only currently available curative treatment option for beta-thalassemia is allogeneic hematopoietic stem cell transplant. However, these transplants are only offered to pediatric patients with matched sibling donors (occurring in less than 25% of all cases), due to the significant risk of transplant-related morbidity and mortality. BLUE reported data from eight subjects with beta-thalassemia major treated with LentiGlobin BB305 drug product. In the first four subjects, each of whom had at least three months of follow up, treatment with BLUE's LentiGlobin BB305 drug product resulted in sufficient hemoglobin production to reduce or eliminate the need for transfusion support among patients with beta-thalassemia major who would otherwise require chronic blood transfusions. These data include the first five subjects treated in BLUE’s ongoing Phase 1/2 Northstar (HGB-204) Study and the first three subjects from its HGB-205 study. BLUE's LentiGlobin drug product aims to treat beta-thalassemia major and severe sickle cell disease by inserting a fully functional human beta-globin gene into the patient's own hematopoietic stem cells ex vivo and then transplanting those modified cells into the patient through infusion, also known as autologous stem cell transplantation. BLUE is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases More about bluebird bio, Inc. (BLUE) at www.bluebirdbio.com. ** BP p.l.c. (BP) In August 2014, BP requested to the United States Supreme Court to review the Fifth Circuit decisions relating to the compensation of claims for losses with no apparent connection to the Deepwater Horizon spill. According to BP, payouts improperly went to businesses that didn’t suffer damage from the 2010 Gulf of Mexico oil spill, a tragedy that killed 11 men and disrupted the lives of millions. On Monday, the Supreme Court turned down BP’s arguments that lower courts misinterpreted settlement terms, declining to rule whether claimants must prove their businesses were damaged by the 2010 Gulf of Mexico oil spill to get compensation. BP said on its website that since May 2010, the company has paid a total of approximately $11 billion to individuals and businesses through various claims processes, with $2.9 billion being paid in 2013. BP has paid almost $1.5 billion for claims, advances and settlements with government entities. BP provides fuel for transportation, energy for heat and light, lubricants to engines, and petrochemicals products worldwide. More about BP plc (BP) at www.bp.com ** Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
|
||||||||||||||||||||||||||||||||||||||||||
|